TegoScience Inc.

KOSDAQ:A191420 Voorraadrapport

Marktkapitalisatie: ₩140.4b

TegoScience Inkomsten in het verleden

Verleden criteriumcontroles 2/6

TegoScience's earnings have been declining at an average annual rate of -7.9%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 1.5% per year. TegoScience's return on equity is 6.6%, and it has net margins of 48.1%.

Belangrijke informatie

-7.9%

Groei van de winst

-8.0%

Groei van de winst per aandeel

Biotechs Groei van de industrie11.7%
Inkomstengroei1.5%
Rendement op eigen vermogen6.6%
Nettomarge48.1%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Are TegoScience Inc.'s (KOSDAQ:191420) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Feb 16
Are TegoScience Inc.'s (KOSDAQ:191420) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

How Much Of TegoScience Inc. (KOSDAQ:191420) Do Insiders Own?

Jan 12
How Much Of TegoScience Inc. (KOSDAQ:191420) Do Insiders Own?

Did You Miss TegoScience's (KOSDAQ:191420) Impressive 137% Share Price Gain?

Dec 08
Did You Miss TegoScience's (KOSDAQ:191420) Impressive 137% Share Price Gain?

Opbrengsten en kosten

Hoe TegoScience geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

KOSDAQ:A191420 Opbrengsten, kosten en inkomsten (KRW Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 246,9743,3523,6132,474
31 Mar 247,194-2,6593,4752,593
31 Dec 237,772-2,3233,6562,576
30 Sep 238,016-1,4042,7162,971
30 Jun 238,134-1,3012,8702,971
31 Mar 238,2022353,7292,027
31 Dec 227,6782653,5341,608
30 Sep 228,4261,3494,854412
30 Jun 228,3411,2544,0141,044
31 Mar 228,1624323,5622,062
31 Dec 218,3001393,9062,328
30 Sep 217,573-4794,1422,421
30 Jun 218,235714,0892,284
31 Mar 218,4559933,5881,992
31 Dec 208,7891,8313,0021,852
30 Sep 208,3231,7612,6711,759
30 Jun 207,5801,3382,5431,803
31 Mar 206,9831,2732,4371,732
31 Dec 196,3468562,4091,700
30 Sep 196,723-2,0582,6121,720
30 Jun 196,849-2,1422,7631,659
31 Mar 197,366-7762,9391,762
31 Dec 187,850-1,8263,1641,743
30 Sep 188,042-3,0713,2261,762
30 Jun 188,245-2,8883,3501,545
31 Mar 188,331-7,5153,4131,583
31 Dec 178,642-6,0213,3481,568
30 Sep 178,568-2,9853,1821,376
30 Jun 178,568-2,6103,0001,433
31 Mar 178,5497762,8791,415
31 Dec 168,3437722,8571,433
30 Sep 168,0491,8422,9071,583
30 Jun 167,9811,8412,8451,678
31 Dec 157,4921,4732,9251,605

Kwaliteitswinsten: A191420 has a large one-off gain of ₩3.7B impacting its last 12 months of financial results to 30th June, 2024.

Groeiende winstmarge: A191420 became profitable in the past.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: A191420 has become profitable over the past 5 years, growing earnings by -7.9% per year.

Versnelling van de groei: A191420 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Winst versus industrie: A191420 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).


Rendement op eigen vermogen

Hoge ROE: A191420's Return on Equity (6.6%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden